Dopamine beta-hydroxylase (DBH) Genetic Variations
Dopamine beta-hydroxylase regulates dopamine levels by enzymatic degradation. Two polymorphisms (DBH5'-Ins/del and DBH 444 g/a) of the DBH gene have been isolated and associated with low DBH activity, cocaine-induced paranoia, and response to cocaine vaccine responsiveness. Although the variants in DBH are not associated with the incidence of schizophrenia or cocaine addiction, the delA haplotype is associated with positive symptoms and therapeutic non-response in schizophrenia. Thus, the DBH gene is not a causative factor in schizophrenia but may modulate psychotic symptoms, severity of the disorder, and therapeutic response to neuroleptic drugs.
The DBH 1368A allele has also been associated with higher quit rates compared to the G allele in patients undergoing smoking cessation therapy with bupropion or placebo (the genotypic effect was independent of therapy).
- Screening for treatment-resistant schizophrenia and predicting response to smoking cessation therapy
- Evaluation of dopamine availability; identifying patients with decreased dopamine availability
- Identifying schizophrenic candidates for neuroleptic therapy
1368A Genotype
Whole blood, saliva, or buccal swab
Collected in lavender top tube (EDTA) or any anticoagulant collection devices.
Stability
- Ambient: 5 days
- Refrigerated: 7 days
- Am J Med Genet B Neuropsychiatr Genet. 2003 Feb;117B(1):33-8. [PMID: 12555232]
- ClinPharmacolTher. 2010 Dec; 88(6): 779–791. [PMID: 20981002]
- Neurosci Lett. 2013 Apr 29;541: 29-33. [PMID: 23458673]
- Am J Med Genet B Neuropsychiatr Genet. 2007 Oct 5;144B(7): 944-5. [PMID: 17503472]